Dr BERTHET Cyril

Fiche personne


coordonnées

Oncodesign Biotechnology
20 rue Jean Mazen
BP 27627
21076 DIJON Cedex

+33 3 80 78 82 60

cberthet@oncodesign.com

Territoire

Bourgogne

Statut

Chercheur

affiliation

Oncodesign

Recherche

Expertises :
- Recherche:Pharmacologie
- Recherche:Modèle animaux
- Recherche:Imagerie
- Industrie:Service

Publications


IFN-gamma AU-rich element removal promotes chronic IFN-gamma expression and autoimmunity in mice.

Hodge DL, Berthet C, Coppola V, Kastenmuller W, Buschman MD, Schaughency PM, Shirota H, Scarzello AJ, Subleski JJ, Anver MR, Ortaldo JR, Lin F, Reynolds DA, Sanford ME, Kaldis P, Tessarollo L, Klinman DM, Young HA

J Autoimmun. 2014 Sep;53:33-45

Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer.

Julien S, Merino-Trigo A, Lacroix L, Pocard M, Goere D, Mariani P, Landron S, Bigot L, Nemati F, Dartigues P, Weiswald LB, Lantuas D, Morgand L, Pham E, Gonin P, Dangles-Marie V, Job B, Dessen P, Bruno A, Pierre A, De The H, Soliman H, Nunes M, Lardier G, Calvet L, Demers B, Prevost G, Vrignaud P, Roman-Roman S, Duchamp O, Berthet C

Clin Cancer Res. 2012 Oct 1;18(19):5314-28

Cdk2 plays a critical role in hepatocyte cell cycle progression and survival in the setting of cyclin D1 expression in vivo.

Hanse EA, Nelsen CJ, Goggin MM, Anttila CK, Mullany LK, Berthet C, Kaldis P, Crary GS, Kuriyama R, Albrecht JH

Cell Cycle. 2009 Sep 1;8(17):2802-9

Voir plus